IPO Year: 2019
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/30/2023 | $5.00 → $1.00 | Equal-Weight → Underweight | Morgan Stanley |
| 12/22/2022 | Outperform → Perform | Oppenheimer | |
| 6/22/2022 | $15.00 | Buy | H.C. Wainwright |
| 4/6/2022 | $10.00 | Buy → Hold | Truist |
| 1/28/2022 | $9.00 | Outperform | Oppenheimer |
| 11/24/2021 | $9.00 | Equal-Weight | Morgan Stanley |
| 10/19/2021 | $12.00 | Buy | Truist Securities |
DEF 14A - Celularity Inc (0001752828) (Filer)
NT 10-Q - Celularity Inc (0001752828) (Filer)
8-K - Celularity Inc (0001752828) (Filer)
8-K - Celularity Inc (0001752828) (Filer)
8-K - Celularity Inc (0001752828) (Filer)
8-K - Celularity Inc (0001752828) (Filer)
10-Q - Celularity Inc (0001752828) (Filer)
8-K - Celularity Inc (0001752828) (Filer)
8-K - Celularity Inc (0001752828) (Filer)
8-K - Celularity Inc (0001752828) (Filer)
FLORHAM PARK, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company, has issued a Corporate Update to Shareholders from Robert J. Hariri, M.D., Ph.D., Founder, Chairman, and CEO. Dear Shareholders, I am pleased to share recent developments at Celularity, including an update on our commercial-stage advanced biomaterial products business. Let me start by reiterating what we said in our announcement last week, which is that we are resolutely committed to regaining full compliance with Nasdaq's listing requirements. We acknowledge the importance of timely filings and have been diligently working with our new auditi
4 - Celularity Inc (0001752828) (Issuer)
4 - Celularity Inc (0001752828) (Issuer)
FLORHAM PARK, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company, today announced that the Nasdaq Listing Qualifications Hearings Panel (the "Hearings Panel") has cancelled the previously scheduled hearing regarding Celularity's non-compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"), as the Company has cured its filing delinquency. The matter is now closed, and Nasdaq has confirmed that Celularity's stock will continue to be listed and traded on The Nasdaq Stock Market. This resolution follows Nasdaq's prior notification on October 16, 2024, indicating that Celularity was not in compliance with the Ru
Celularity Raises Full Year 2024 Expected Net Sales Guidance to $54 Million to $60 Million, Compared to Previous Guidance of $50 Million to $56 MillionOctober Expected Net Sales of $8.3 Million to $8.9 Million Marks the Highest Single-Month Figure in its HistoryCelularity Filed its Second Quarter Form 10-Q and is Now Current With its Quarterly Report Filings FLORHAM PARK, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity") a regenerative and cellular medicine company, today announced that it has increased expected net sales guidance for the full year 2024 to $54 million to $60 million, up from $50 million to $56 million previously announced in February. Th
FLORHAM PARK, N.J., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company, today announced that it has requested a hearing before the Nasdaq Hearings Panel (the "Hearings Panel") the Nasdaq Listing Qualifications Department's determination regarding Celularity's non-compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule") and to seek an additional extension to regain compliance. As previously announced, Celularity received formal notice from Nasdaq on August 22, 2024, indicating non-compliance with the Rule due to the delayed filing of its quarterly reports on Forms 10-Q for the periods ended March 31, 2024, and Ju
FLORHAM PARK, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company, has issued a Corporate Update to Shareholders from Robert J. Hariri, M.D., Ph.D., Founder, Chairman, and CEO. Dear Shareholders, I am pleased to share recent developments at Celularity, including an update on our commercial-stage advanced biomaterial products business. Let me start by reiterating what we said in our announcement last week, which is that we are resolutely committed to regaining full compliance with Nasdaq's listing requirements. We acknowledge the importance of timely filings and have been diligently working with our new auditi
FLORHAM PARK, N.J., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) (the "Company"), a regenerative medicine company developing and commercializing placental-derived technologies, today announced that it has received a formal notice from the Listing Qualifications department of the Nasdaq Stock Market LLC ("Nasdaq") on October 16, 2024, indicating that the Company is subject to delisting due to its inability to timely file its Forms 10-Q for the the periods ended March 31, 2024, and June 30, 2024 (the "Forms 10-Q") within the prescribed 180-day compliance period. Nasdaq's notice has no immediate effect on the listing of the Company's common stock and warrants, which continu
FLORHAM PARK, N.J., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company, today announced that it had added to its commercial portfolio of placental-derived advanced biomaterial products with the acquisition of Rebound, a full thickness placental-derived allograft matrix product, from Sequence LifeScience, Inc. ("Sequence"). "Rebound adds to our portfolio of placental-derived advanced biomaterial products, sales of which through the first half of 2024 were in excess of $24 million, which is greater than our full year sales in 2023," said Robert J. Hariri, M.D., Ph.D., Chairman, CEO and founder of Celularity. "We expec
FLORHAM PARK, N.J., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, today announced that Robert J. Hariri, M.D., Ph.D., Chairman, CEO and founder, will present at H.C. Wainwright's 26th Annual Global Investment Conference being held at the Lotte New York Palace Hotel in New York City on September 9-11, 2024. H.C. Wainwright 26th Annual Global Investment ConferenceDate: Monday, September 9, 2024Time: 12:30 p.m. ET Location: Lotte New York Palace Hotel, New YorkSpeaker: Robert J. Hariri, M.D., Ph.D., Founder, Chairman & CEO
FLORHAM PARK, N.J., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) (the "Company"), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today the appointment of Richard J. Berman, to its Board of Directors. Mr. Berman is an experienced public company director whose career spans over 40 years of venture capital, senior management, and merger and acquisitions experience. He has served as a director and/or officer of over a dozen public and private companies in the last five years, six of which have reached over one billion dollars in market value. Previously, Mr. Berman worked at Gol
FLORHAM PARK, N.J., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) (the "Company"), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced that on August 22, 2024, the Company received notification from the Listing Qualifications department of the Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Form 10-Q for the quarter ended June 30, 2024 ("Q2 2024 Form 10-Q"), and because the Company remains delinquent in filing its Form 10-Q for the quarter ended June 30, 2024 ("Q2 2024 Form 10-Q"), it does not comply with the Nasdaq continued listing requi
For the first quarter 2024, Celularity expects combined net sales of $14.8 million for its advanced biomaterial product and biobanking businesses, compared to the $10.25 million to $11.5 million guidance range previously announced in February. Celularity's expected combined net sales for the first half 2024 are $25.8 to $27.8 million compared to $6.9 million of net sales in the first of 2023 at the midpoint of the 2024 range. Celularity reiterated it is on track to file a 510(k) premarket submission for its Celularity Tendon Wrap in the second half 2025, the first of three planned advanced biomaterial medical devices. FLORHAM PARK, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- Celularity Inc
4 - Celularity Inc (0001752828) (Issuer)
3 - Celularity Inc (0001752828) (Issuer)
4 - Celularity Inc (0001752828) (Issuer)
4 - Celularity Inc (0001752828) (Issuer)
4 - Celularity Inc (0001752828) (Issuer)
4 - Celularity Inc (0001752828) (Issuer)
4 - Celularity Inc (0001752828) (Issuer)
4 - Celularity Inc (0001752828) (Issuer)
4 - Celularity Inc (0001752828) (Issuer)
4 - Celularity Inc (0001752828) (Issuer)
Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that the Journal for ImmunoTherapy of Cancer, a peer-reviewed online journal of the Society for Immunotherapy of Cancer, published data highlighting the potential advantages of Celularity's T-Cell platform for future immunotherapies including chimeric antigen receptor (CAR-T) therapies. The data compared CAR-T cells derived from Celularity's proprietary T cell platform with CAR-T cells derived from healthy adult peripheral blood mononuclear cells (PBMCs). CAR-T cells generated from its T-Cell platf
Expects the First Quarter of 2024 will be the 4th consecutive quarter of both sequential and quarter-on-quarter net sales growth Implements plan to reduce 2024 selling, general & administrative expenses (SG&A), executive cash compensation, reinforces management's alignment of incentives with shareholders on corporate successFLORHAM PARK, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity") a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, today announced that its expected net sales for the first quarter of 2024 are trending ahead of the expectations it announced in February for its advanc
Celularity Inc. (NASDAQ:CELU) ("Celularity"), a biotechnology company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that it will present in vitro data from its investigational natural killer (NK) cell therapy programs at this year's American Society of Gene and Cell Therapy (ASGCT) Annual Meeting. The preclinical data, which suggest that Celularity's placenta-derived unmodified natural killer (NK) cells (CYNK-001) and genetically modified NK cells (CYNK-201) may serve as potent and selective senolytic agents for use in addressing age-related diseases, will be presented on May 9, 2024. Senescent cells are key drivers in the process o
Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted a Healthcare Common Procedure Coding System (HCPCS) Q code for Biovance® 3L, a tri-layer allograft derived from placental tissue intended for use as a biological membrane covering barrier or wrap that acts as a scaffold for restoration of functional tissue in partial- and full-thickness, acute and chronic wounds. The designated HCPCS Q code is Q4283 and is available starting April 1, 2024. "The HCPCS Q code approval by CMS further recogniz
Gainers NuCana (NASDAQ:NCNA) shares moved upwards by 110.6% to $0.81 during Wednesday's pre-market session. The market value of their outstanding shares is at $42.7 million. Kintara Therapeutics (NASDAQ:KTRA) stock moved upwards by 25.0% to $0.1. The market value of their outstanding shares is at $4.0 million. Agile Therapeutics (NASDAQ:AGRX) stock moved upwards by 19.34% to $0.87. The company's market cap stands at $2.5 million. Compass Therapeutics (NASDAQ:CMPX) stock moved upwards by 14.97% to $2.38. The company's market cap stands at $303.4 million. HUTCHMED (China) (NASDAQ:HCM) stock increased by 14.04% to $18.62. The company's market cap stands at $3.1 billion. Qilian Intl Hldg G
SC 13D/A - Celularity Inc (0001752828) (Subject)
SC 13G/A - Celularity Inc (0001752828) (Subject)
SC 13D/A - Celularity Inc (0001752828) (Subject)
SC 13G/A - Celularity Inc (0001752828) (Subject)
SC 13D/A - Celularity Inc (0001752828) (Subject)
SC 13G/A - Celularity Inc (0001752828) (Subject)
SC 13G - Celularity Inc (0001752828) (Subject)
SC 13G/A - Celularity Inc (0001752828) (Subject)
SC 13G - Celularity Inc (0001752828) (Subject)
SC 13G/A - Celularity Inc (0001752828) (Subject)
Morgan Stanley downgraded Celularity from Equal-Weight to Underweight and set a new price target of $1.00 from $5.00 previously
Oppenheimer downgraded Celularity from Outperform to Perform
H.C. Wainwright initiated coverage of Celularity with a rating of Buy and set a new price target of $15.00
Truist downgraded Celularity from Buy to Hold and set a new price target of $10.00
Oppenheimer initiated coverage of Celularity with a rating of Outperform and set a new price target of $9.00
Morgan Stanley initiated coverage of Celularity with a rating of Equal-Weight and set a new price target of $9.00
Truist Securities initiated coverage of Celularity with a rating of Buy and set a new price target of $12.00
FLORHAM PARK, N.J., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) (the "Company"), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today the appointment of Richard J. Berman, to its Board of Directors. Mr. Berman is an experienced public company director whose career spans over 40 years of venture capital, senior management, and merger and acquisitions experience. He has served as a director and/or officer of over a dozen public and private companies in the last five years, six of which have reached over one billion dollars in market value. Previously, Mr. Berman worked at Gol
FLORHAM PARK, N.J., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) (Celularity), a biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies and advanced biomaterial products, today announced the appointment of Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors. Dr. Ling, a distinguished academic and military physician-scientist with a strong background in regenerative medicine and a deep commitment to advancing healthcare, will bring invaluable expertise and insights to Celularity as it continues to pioneer innovative therapies for patients in need. Throughout his career, Dr. Ling has made significant contributions to regenera
FLORHAM PARK, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a biotechnology company developing placental-derived allogeneic cell and biomaterial therapies, today announced that Paul Graves has been appointed Senior Vice President, Chief Communications Officer, effective January 2, 2023. Mr. Graves is a seasoned communications professional who brings more than 30 years of strategic communications experience in the biopharmaceutical industry. He has deep expertise in corporate reputation, global research and development, product launch and promotion, investor relations and public affairs. He will provide senior strategic communications leadership for C
Announced first patient treated in Phase 1/2a clinical trial for CYNK-101 in first-line advanced HER2 positive gastric and gastroesophageal junction (G/GEJ) cancerAppointed Adrian Kilcoyne, M.D., M.P.H., M.B.A., as Chief Medical Officer and announced the promotion of two senior executives and the formation of a new Executive CommitteePresenting an abstract at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting that supports the scientific rationale of the CYNK-101Strengthened balance sheet using a combination of a $150 million at-the-market (ATM) facility and a $150 million pre-paid advance agreement FLORHAM PARK, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (NAS
FLORHAM PARK, N.J., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies, today announced that Adrian Kilcoyne, M.D., M.P.H., M.B.A., has been appointed Executive Vice President, Chief Medical Officer (CMO) and Head of Global Medical Affairs, Patient Safety and Patient Affairs, effective today. Dr. Kilcoyne brings over 15 years of clinical experience to Celularity, having previously served in R&D, medical affairs, and commercialization roles, primarily focused on oncology. He has a track record of advancing early-stage clinical programs through commercialization and will p
FLORHAM PARK, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced the appointment of Diane Parks to its Board of Directors. Ms. Parks, an executive with deep experience in the commercialization of novel immuno-oncology therapies, has led the successful launch of numerous hematology and cancer therapies at large pharmaceutical and biotech companies, including Kite Pharma, Inc. (now part of Gilead Sciences, Inc.), Amgen Inc., and Genentech, Inc. (now part of Roche Holdings, Inc.). "It is with great pleasure we welcome Diane to the Cel
FLORHAM PARK, N.J., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU), a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic therapies, today announced the appointment of Andrew L. Pecora, M.D., F.A.C.P., C.P.E., as President effective today. Reporting to Robert J. Hariri, M.D., Ph.D., Chairperson and Chief Executive Officer, Dr. Pecora will provide senior leadership to advance Celularity's clinical pipeline toward U.S. Food and Drug Administration (FDA) approval, including responsibility for preclinical and clinical development and regulatory affairs. "It is with great pleasure that we announce Andrew's appointment as Celularity's P